Exclusive

Publication

Byline

मकान सूचीकरण के लिए ग्राम पंचायतों में बजी डुगडुगी

फर्रुखाबाद कन्नौज, मई 4 -- फर्रुखाबाद, संवाददाता। जनगणना 2027 की तैयारियां जोरों पर शुरू हो गई हैं। जनगणना में किसी तरह की कोई दिक्कतें न हों इसको लेकर ग्राम पंचायतों ने बैठकों के लिए रोस्टर भी जारी क... Read More


अखिल भारतीय आयुर्विज्ञान संस्थान देवघर में मना अग्नि सुरक्षा सप्ताह

देवघर, मई 4 -- देवीपुर, प्रतिनिधि। अखिल भारतीय आयुर्विज्ञान संस्थान देवघर में सोमवार को अग्नि सुरक्षा सप्ताह 2026 मनाया गया। अग्नि सुरक्षा सप्ताह 4 से 10 मई तक मनाया जाना है। अग्नि सुरक्षा सप्ताह 2026... Read More


एक माह में मिलेगा विद्युत सब स्टेशन, मेडिकल कॉलेज का आईपीडी भवन जल्द होगा शुरू

हरदोई, मई 4 -- हरदोई। मेडिकल कॉलेज के आईपीडी (अंत: रोगी विभाग) भवन को एक माह के भीतर विद्युत सब स्टेशन मिलने की उम्मीद है। लंबे समय से पर्याप्त बिजली व्यवस्था न होने के कारण भवन का संचालन शुरू नहीं हो... Read More


NATIONAL OCEANIC AND ATMOSPHERIC ADMINISTRATION ISSUES NOTICE: NEW ENGLAND FISHERY MANAGEMENT COUNCIL; PUBLIC MEETING

WASHINGTON, May 4 -- National Oceanic and Atmospheric Administration has issued a notice called: New England Fishery Management Council; Public Meeting. The notice was published in the Federal Regist... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and E... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and T... Read More


Singapore Clinical Trial: A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Investigator’s Choice of TKI Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined... Read More


Singapore Clinical Trial: 'Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the post-operative survival of glaucoma drainage devices'

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the post... Read More


Singapore Clinical Trial: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) ... Read More


Singapore Clinical Trial: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.

Singapore, May 4 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) ... Read More